Health Care

CEO Michael Farrell’s balanced 10b5‑1 trade shows disciplined, long‑term confidence in ResMed, reassuring investors of steady leadership and value‑creation focus.

Relay Therapeutics insider selling by CEO Sanjiv Patel signals a steady 10b5‑1 exit strategy amid a high‑growth biotech, urging investors to watch clinical milestones and market moves.

Analyze Martine Rothblatt’s latest United Therapeutics insider trades – see how 10b5‑1 sales and trust holdings reveal a balanced liquidity strategy.

Insider trade: Edwards Lifesciences CVP Lippis Daniel buys 619 shares at $72.68, sells at $85.65, signaling confidence in its TAVR business and future upside.

Repligen insider Robb’s new RSU grant signals long‑term confidence in the company’s BioLife acquisition and bioprocessing strategy, hinting at potential upside for investors.

Insider buying spurs hope for Alaunos Therapeutics as key investors buy at steep discounts, hinting at a potential rebound if clinical milestones are met.

Pacific Biosciences insider trades reveal a strategic buy‑sell pattern: Gibson James R II’s 500k share purchase at $1.18 signals confidence in PACB’s SMRT sequencing future.

Teva insider trades reveal a strategic shift—executives buy back shares after selling at highs, signaling confidence in its psychiatric pipeline and future growth.

Insider buying by AstraZeneca SVP Sharma Mani boosts confidence in the drugmaker’s oncology pipeline and $1 billion capital plan.

Neurocrine CMO Roberts Eiry’s 51k‑share stake signals deep insider confidence—insight on options, RSUs, and what it means for investors and the company’s future.